Ribosome Recycling as a Drug Target
News Dec 07, 2016
Multidrug-resistant bacteria – strains that have become resistant to conventional antibiotics – pose an increasingly serious medical problem, which underlines the urgent need to develop new antibiotics that attack novel targets. “Many of the most effective antibiotics act by inhibiting various steps in protein synthesis on bacterial ribosomes,” as LMU biochemist Daniel Wilson points out. The search is now on for agents that interfere with aspects of the process that have so far been overlooked in this context. One of these processes is the recycling of stalled ribosomes. Wilson and his research group have just completed a comprehensive structural study of ribosome recycling. The results of the study, which appears in the leading journal Nature, may identify promising points of attack for future antibiotics.
Ribosomes are the organelles that translate the nucleotide sequences encoded in messenger RNA molecules (mRNAs) into the amino-acid sequences of the corresponding proteins. The ribosome “reads” the nucleotide sequence in a fixed direction and is released from the mRNA only when it reaches a defined termination signal. Errors in synthesis or processing may, however, lead to the production of mRNAs that lack termination signals, causing the ribosome to stall while still attached to the mRNA and the growing protein. Cells have evolved several ways of detaching stalled ribosomes from the truncated mRNAs and recycling them for re-use. Wilson’s team has now employed cryo-electron microscopy to determine the structure of the bacterial recycling factor ArfA. Their analysis reveals how ArfA recognizes the stalled ribosome on a defective mRNA and recruits a so-called release factor, which detaches the incomplete protein. This then enables the stalled ribosome to be released from the mRNA in the normal manner by dissociation into its two component subunits. The subunits are then free to interact with another mRNA, thus allowing protein synthesis to proceed.
“Our results could facilitate the development of new antibiotics that act by inhibiting ArfA-mediated ribosome recycling,” says Wilson. Since recycling of human ribosomes is dependent on factors that are unrelated to ArfA, such inhibitors should act specifically on the bacterial ribosome, and kill the bacterial cell by gradually cutting off the supply of free ribosomes.
Story from Ludwig-Maximilians University of Munich. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Huter, P., Müller, C., Beckert, B., Arenz, S., Berninghausen, O., Beckmann, R., & Wilson, D. N. (2016). Structural basis for ArfA–RF2-mediated translation termination on mRNAs lacking stop codons. Nature. doi:10.1038/nature20821
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE